Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Protein Degradation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NEDD8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NEDD8 Recombinant Protein / Mutant Protein (e.g., K48R, Vinyl Sulfone) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View NEDD8 Products |
| Gene Delivery | NEDD8 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View NEDD8 Products |
| Benchmark Ab | Anti-NEDD8 Recombinant Antibody Recombinant positive control for western blotting and immunoprecipitation. |
View NEDD8 Products |
| Validator | NEDD8 siRNA Set For knockdown verification in cell-based assays. |
View NEDD8 Products |
| Related Target A | NAE1 (UBA3/APPBP1) NEDD8-activating enzyme subunit 1, the primary upstream initiator of neddylation. |
View NAE1 Products |
| Related Target B | SENP8 The specific protease responsible for NEDD8 de-conjugation (de-neddylation). |
View SENP8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro Neddylation Cascades | Recombinant NEDD8 with precise C-terminal glycine preservation, verified by Mass Spectrometry. |
| De-neddylating Enzyme Screening | NEDD8-Vinyl Sulfone (NEDD8-VS) and mutant derivatives strictly purified under native conditions. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for target-specific knockdown and assay validation |
Live NEDD8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NEDD8 therapeutics is intensifying, with major players shifting focus from traditional global protein degradation inhibitors to selective pathway modulators and PROTAC-adjacent mechanisms. As first-generation therapies like Pevonedistat (MLN4924) reach advanced clinical stages, the next wave of R&andD is targeting specific de-neddylating enzymes (such as SENP8) and utilizing neddylation machinery for targeted protein degradation (TPD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (NAE) | Takeda, Millennium | AML, MDS, Solid Tumors | Enzymatic Assay (Need high-purity recombinant NEDD8 and NAE1) |
| Deneddylase Inhibitors | Academic Spin-offs, Biotech | Inflammation, Oncology | Activity-based profiling (Need mutant/functionalized NEDD8-VS) |
| Neddylation-Targeting PROTACs | Arvinas, Kymera, C4 Therapeutics | Refractory Cancers | Ubiquitin/NEDD8 transfer assays (Need high-purity Cullin proteins) |